The main aim of this study is to evaluate the value of intraumbilical vein injection of saline, oxytocin or prostaglandin F2α in affecting the separation and expulsion of the retained placenta and if there are complications for this modality of the treatment.
After vaginal delivery retention of the placenta carries a substantial risk to maternal health. Manual removal of retained placenta is not without dangers and any other treatment that might reduce the need to perform this procedure is of special interest. Manual removal of the placenta carries the risk of hemorrhage, infection, rupture of the uterus, trauma to the cervix or the vagina, beside the complications of general anaesthesia required for the procedure.
There are some reports that intraumbilical vein injection of oxytocin is effective in delivering retained placenta.
The trial for usage of PGF2α injection into the umbilical vein to deliver retained placenta is a new one which reported excellent results as a new modality of treatment that could minimize or eliminate the need to resort to manual removal of the placenta.
The study included 60 women in whom placenta failed to be delivered within 30 minutes after baby birth. They were classified into four groups.
Croup I: Intraumbilical vein injection of PGF2α.
Group II: Intraumbilical vein injection of oxytocin.
Group III: Intraumbilical vein injection of normal saline.
Group IV: Expectant management with on injection is carried out.
The study has shown that intraumbilical injection of PGF2α is highly effective (93.33% success rate) with mean injection expulsion interval 8.5 minutes. Oxytocin injection was partially successful (46.67% success rate) with mean injection- expulsion interval 13 min.
PGF2α injection has a significantly higher success rate compared to oxytocin (P |
